Article Text

Download PDFPDF
Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors TW, FSS, AD, SD, KP, BW, BH and JB were responsible for the patient management, clinical data collection, sample collection and immunisation. MA, SS and US were involved in sample analysis. AB-N was responsible for statistical analysis and graphical presentation. NB, TW, FSS and US prepared and revised draft of the manuscript. NB supervised the study. All authors have read and revised manuscript, if required.

  • Funding The study was supported by grant of Mercator Stiftung and BMBF grant noChro.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles